NCT07915544
A Study of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Dose-limiting toxicities (DLTs) of GKL-006Allo injection
Timeframe: 28 days after the first dose of GKL-006Allo
Frequency of adverse events (AEs) and serious adverse events (SAEs)
Timeframe: From first dose through end of study (approximately 52 weeks after first dose)
Change from baseline in systolic blood pressure
Timeframe: Baseline through end of study (approximately 52 weeks after first dose)
Change from baseline in diastolic blood pressure
Timeframe: Baseline through end of study (approximately 52 weeks after first dose)
Change from baseline in pulse rate
Timeframe: Baseline through end of study (approximately 52 weeks after first dose)
Change from baseline in respiratory rate
Timeframe: Baseline through end of study (approximately 52 weeks after first dose)
Change from baseline in body temperature
Timeframe: Baseline through end of study (approximately 52 weeks after first dose)
Number of participants with clinically significant changes from baseline in physical examination findings
Timeframe: Baseline through end of study (approximately 52 weeks after first dose)
Number of participants with clinically significant shifts from baseline in laboratory test results
Timeframe: Baseline through end of study (approximately 52 weeks after first dose)
Number of participants with abnormal 12-lead electrocardiogram (ECG) findings
Timeframe: Baseline through end of study (approximately 52 weeks after first dose)
Secondary (35)
Assessment of SpondyloArthritis International Society (ASAS)20 response rate
Assessment of SpondyloArthritis International Society (ASAS)40 response rate
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)50 response rate
Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score
Change from baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) score
Show 30 moreShow less
Change from baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) score
Change from baseline in total back pain score
Change from baseline in participant's global assessment of disease activity (PGA)
Change from baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
Change from baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
Change from baseline in Assessment of SpondyloArthritis international Society Health Index (ASAS HI) score
Change from baseline in 44-joint swollen joint count
Change from baseline in dactylitis count
Changes from baseline in erythrocyte sedimentation rate (ESR)
Changes from baseline in C-reactive protein (CRP)
Proportion of participants achieving ankylosing spondylitis disease activity score using C-reactive protein (ASDAS-CRP) low disease activity (ASDAS < 2.1) and clinical remission (ASDAS < 1.3)
Change from baseline in Hospital Anxiety and Depression Scale (HADS) score
Change from baseline in Pittsburgh Sleep Quality Index (PSQI) score
Changes from baseline in sacroiliac joint inflammation on MRI assessed by the Spondyloarthritis Research Consortium of Canada (SPARCC) score
Peak concentration (Cmax) of invariant natural killer T (iNKT) cells in peripheral blood
Time to peak concentration (Tmax) of iNKT cells in peripheral blood
Area under the concentration-time curve from time zero to the last measurable concentration (AUC0-t) of iNKT cells in peripheral blood
Area under the concentration-time curve from time zero to infinity (AUC0-inf) of iNKT cells in peripheral blood
Half-life (t1/2) of iNKT cells in peripheral blood
Last detectable concentration (Clast) of iNKT cells in peripheral blood
Time of last measurable concentration (tlast) of iNKT cells in peripheral blood
Change from baseline in NK cells (CD3- CD56+)
Change from baseline in activated NK cells (CD3- CD56+ CD69+)
Change from baseline in T cells (CD8+)
Change from baseline in myeloid-derived suppressor cells (MDSCs, CD11b+ CD33+)
Change from baseline in plasma interferon-gamma (IFN-gamma) concentration
Change from baseline in plasma tumor necrosis factor-alpha (TNF-alpha) concentration
Change from baseline in plasma interleukin-6 (IL-6) concentration
Change from baseline in plasma interleukin-17A (IL-17A) concentration
Incidence of anti-drug antibodies (ADA) against invariant natural killer T (iNKT) cell surface antigens
Arms and interventions
GKL-006Allo InjectionExperimental
Participants receive GKL-006Allo injection by intravenous infusion once every two weeks for up to 11 doses. Participants are assigned to one of two dose levels, a low dose of (3.0±0.9)×10\^8 cells/m2 or a high dose of (9.0±2.7)×10\^8 cells/m2, with the low-dose level enrolled first and the high-dose level opened after safety review per the dose-escalation rules.
Biologicals: GKL-006Allo
Sites
1 site in 1 country
- First Medical Center of Chinese PLA General HospitalBeijing, China